Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 7/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.41 |
| ▸ | PDE4A | P27815 | 2/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 4/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22123857 | 0.83 | SNCA (0.39) | LIPEAR | |
| SCHEMBL30143835 | 0.82 | PDE4A (0.43) | LIPEPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL13860167 | 0.82 | PDE4A (0.43) | LIPEPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL1130864 | 0.82 | LIPE (0.43) | LIPEPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL1128760 | 0.80 | PDE4A (0.44) | LIPEPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL29792085 | 0.79 | PDE4A (0.43) | LIPEPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL4357613 | 0.79 | PDE4A (0.43) | LIPEPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL1129675 | 0.78 | LTA4H (0.43) | LIPEPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL9755 | 0.77 | LPL (0.43) | LIPELPLLIPG | |
| SCHEMBL29382961 | 0.77 | LPL (0.43) | LIPELPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481733-B2 | Substituted imidazopyr- and imidazotri-azines | OSI Pharmaceuticals, LLC (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2283020-B1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARM INC (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2283020-A1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI Pharmaceuticals, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009143051-A1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | ABL1, TPMT, CYP2C19 | LIPE 4448/4885MGLL 4867/4885PDE4B 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.